Background: Neurofilament proteins as biomarkers of axonal degeneration have the potential to improve our capacity to predict and monitor neurological outcome in experimental autoimmune encephalitis (EAE), a model of multiple sclerosis (MS). We urgently need more accurate early predictive markers to direct the clinician when to provide neuroprotective therapy.
Aims: To highlight the possible roles of neurofilament proteins in physiological and pathophysiological processes in the MS.
Materials and methods: Fifty female Wistar rats with MOG35-55 peptide induced EAE were randomly divided into two parts: control group and EAE group. All of them were along with expanded disability status scale (EDSS). The mice were sacrificed on day 0, 1, 3, 7, 14, and 28 after the first immunization. Supernatant and pellet were separated at the same time. The degradation rates of NF in the brain nerve and spinal cord of each rat were measured by Western Blotting.
Statistical analysis: The data were expressed as mean ± SD. Statistical analysis was performed with one-way analysis of variance (ANOVA), followed by LSD's post-hoc tests, which was provided by SPSS 23.0 statistical software.
Results and conclusions: Neurofilament light protein may be more useful as a measure of ongoing neurodegenerative activity in EAE, which would make this protein a potential candidate for use as a surrogate marker for assessment of treatments aimed at reducing axonal injury. Future studies are warranted to support or refute the value neurofilament in clinical practice.
Keywords: Autoimmune; axonal degeneration; experimental allergic encephalomyelitis; neurofilament protein.